Thus, MDA-MB-231 breast cancer cells, which express low levels of endogenous EBP50, were transfected with an EBP50 expression plasmid to overexpress EBP50, and MCF-7 breast cancer cells, which express high levels of endogenous EBP50, were transfected with an EBP-RNAi plasmid to knock down its expression. This evidence concerns the gene EBP and breast carcinoma.